X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (122) 122
humans (118) 118
hematology (77) 77
chronic myelogenous leukemia (56) 56
animals (53) 53
leukemia, myelogenous, chronic, bcr-abl positive - pathology (53) 53
imatinib mesylate (48) 48
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (47) 47
hemic and lymphatic diseases (43) 43
abridged index medicus (42) 42
mice (41) 41
chronic myeloid-leukemia (40) 40
chronic myeloid leukemia (38) 38
bcr-abl (34) 34
benzamides (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - genetics (34) 34
stem cells (32) 32
oncology (31) 31
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (30) 30
neoplastic stem cells - pathology (28) 28
leukemia (27) 27
protein kinase inhibitors - pharmacology (27) 27
stem-cells (27) 27
imatinib (26) 26
cancer (25) 25
neoplastic stem cells - drug effects (25) 25
pyrimidines - pharmacology (25) 25
apoptosis (24) 24
male (24) 24
female (23) 23
fusion proteins, bcr-abl - metabolism (23) 23
neoplastic stem cells - metabolism (23) 23
fusion proteins, bcr-abl - genetics (21) 21
pyrimidines - therapeutic use (21) 21
piperazines - therapeutic use (20) 20
cell biology (19) 19
protein kinase inhibitors - therapeutic use (19) 19
apoptosis - drug effects (18) 18
piperazines - pharmacology (18) 18
cml (17) 17
neoplasms (17) 17
antineoplastic agents - therapeutic use (16) 16
chronic-phase (16) 16
hematopoietic stem cells - metabolism (16) 16
drug resistance, neoplasm (15) 15
in-vitro (15) 15
progenitor cells (15) 15
signal transduction (15) 15
tumor cells, cultured (15) 15
tyrosine kinase inhibitor (15) 15
antineoplastic agents - pharmacology (14) 14
cells, cultured (14) 14
k562 cells (14) 14
research (14) 14
cell line, tumor (13) 13
expression (13) 13
fusion proteins, bcr-abl - antagonists & inhibitors (13) 13
medicine, research & experimental (13) 13
philadelphia-chromosome (13) 13
tyrosine kinase (13) 13
tyrosine kinase inhibitors (13) 13
adult (12) 12
antigens, cd34 - metabolism (12) 12
cell survival - drug effects (12) 12
flow cytometry (12) 12
hematopoietic stem cells - drug effects (12) 12
middle aged (12) 12
tyrosine (12) 12
analysis (11) 11
cd34 cells (11) 11
colony-stimulating factor (11) 11
dasatinib (11) 11
drug synergism (11) 11
hematopoietic stem cells (11) 11
hematopoietic stem-cells (11) 11
kinases (11) 11
philadelphia chromosome (11) 11
article (10) 10
cell proliferation - drug effects (10) 10
chronic myeloid leukaemia (10) 10
gene expression regulation, leukemic (10) 10
protein-tyrosine kinases - antagonists & inhibitors (10) 10
reverse transcriptase polymerase chain reaction (10) 10
aged (9) 9
bone-marrow (9) 9
cell survival (9) 9
drug resistance (9) 9
fusion proteins, bcr-abl (9) 9
hematopoietic progenitors (9) 9
hematopoietic stem cell transplantation (9) 9
hematopoietic stem cells - cytology (9) 9
hematopoietic stem cells - pathology (9) 9
leukemia, myelogenous, chronic, bcr-abl positive (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (9) 9
mice, transgenic (9) 9
myeloid neoplasia (9) 9
phosphorylation (9) 9
protein kinase inhibitors (9) 9
resistance (9) 9
therapy (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Experimental Hematology, ISSN 0301-472X, 2016
Abstract Advances in the design of targeted therapies for the treatment of chronic myeloid leukaemia (CML) have transformed the prognosis for patients... 
Advanced Basic Science | Hematology, Oncology and Palliative Medicine
Journal Article
The Journal of Experimental Medicine, ISSN 0022-1007, 10/2011, Volume 208, Issue 11, pp. 2155 - 2158
Journal Article
Blood, ISSN 0006-4971, 03/2013, Volume 121, Issue 10, pp. 1824 - 1838
Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid leukemia (CML) but do not eliminate leukemia stemcells (LSCs), which... 
ADHESION | IMATINIB | NICHE | FIBRONECTIN | RESISTANCE | STABILIZES | HEMATOLOGY | UP-REGULATION | EXPRESSION | CHRONIC MYELOID-LEUKEMIA | REMISSION | Cadherins - metabolism | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Tumor Microenvironment | Drug Resistance, Neoplasm | Gene Expression Profiling | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Mesenchymal Stem Cells - drug effects | Biomarkers, Tumor - metabolism | Neoplastic Stem Cells - pathology | Phosphorylation - drug effects | Tumor Cells, Cultured | Cadherins - genetics | Real-Time Polymerase Chain Reaction | Bone Marrow - drug effects | RNA, Messenger - genetics | Reverse Transcriptase Polymerase Chain Reaction | beta Catenin - metabolism | Blotting, Western | beta Catenin - genetics | Mesenchymal Stem Cells - pathology | Fusion Proteins, bcr-abl - genetics | Animals | Mice, Nude | Bone Marrow - pathology | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Fusion Proteins, bcr-abl - metabolism | Index Medicus | Abridged Index Medicus | Myeloid Neoplasia
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 10/2017, Volume 23, Issue 10, pp. 1234 - 1240
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs)... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | KINASE-ACTIVITY | COMPLETE MOLECULAR REMISSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | DISCONTINUATION | CELL BIOLOGY | BCR | METABOLISM | FATTY-ACID OXIDATION | IMATINIB | SUPPORTING ASPARTATE BIOSYNTHESIS | DIFFERENTIATION | Metabolomics | Up-Regulation | Minocycline - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Minocycline - analogs & derivatives | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Oxidative Phosphorylation - drug effects | Imatinib Mesylate - therapeutic use | Neoplastic Stem Cells - metabolism | Mass Spectrometry | Chromatography, Liquid | Female | Tumor Cells, Cultured | Drug Therapy, Combination | Cell Survival - drug effects | Tumor Stem Cell Assay | Imatinib Mesylate - pharmacology | Mitochondria - metabolism | Mitochondria - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Phenformin - pharmacology | Hypoglycemic Agents - pharmacology | Xenograft Model Antitumor Assays | Animals | Protein Kinase Inhibitors - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice, Inbred NOD | Anti-Bacterial Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | In Vitro Techniques | Drug Resistance, Neoplasm - drug effects | Oxidative stress | Care and treatment | Genotype | Development and progression | Genetic aspects | Chronic myeloid leukemia | Health aspects | Phosphorylation | Transformation | Target recognition | Oxidative metabolism | Leukemia | Xenotransplantation | Disease resistance | Oxidation resistance | Mitochondria | Transformed cells | CD38 antigen | Xenografts | Drug therapy | Protein-tyrosine kinase | Chronic illnesses | Tyrosine | CD34 antigen | Imatinib | Cell survival | Myeloid leukemia | Minimal residual disease | Metabolism | Survival | Oxidative phosphorylation | Antibiotics | Stem cells | Tigecycline | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 6, pp. 1501 - 1510
Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated... 
CHRONIC MYELOGENOUS LEUKEMIA | SELECTIVE INHIBITOR | POSITIVE CELLS | COLONY-STIMULATING FACTOR | TYROSINE KINASE | PHILADELPHIA-CHROMOSOME | ACUTE LYMPHOBLASTIC-LEUKEMIA | RESIDUAL DISEASE | HEMATOLOGY | HEMATOPOIETIC PROGENITORS | IMATINIB MESYLATE | Antigens, CD34 - metabolism | Apoptosis - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Dose-Response Relationship, Drug | STAT5 Transcription Factor - metabolism | Flow Cytometry | Neoplastic Stem Cells - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | HEK293 Cells | Neoplastic Stem Cells - pathology | Cell Survival - drug effects | Dasatinib | Mice, Transgenic | Nuclear Proteins - metabolism | Gene Expression Regulation, Leukemic | Pyrimidines - pharmacology | Gene Knockout Techniques | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Fusion Proteins, bcr-abl - genetics | Animals | Fusion Proteins, bcr-abl - antagonists & inhibitors | K562 Cells | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Adaptor Proteins, Signal Transducing - metabolism | Fusion Proteins, bcr-abl - metabolism | Index Medicus | Abridged Index Medicus | Myeloid Neoplasia
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2014, Volume 123, Issue 25, pp. 3951 - 3962
Journal Article
Cell, ISSN 0092-8674, 09/2016, Volume 167, Issue 1, pp. 45 - 46
Effective differentiation therapy for acute myeloid leukemia (AML) has been restricted to a small subset of patients with one defined genetic abnormality.... 
BIOCHEMISTRY & MOLECULAR BIOLOGY | LEUKEMIA | CELL BIOLOGY | Cell Differentiation | Lifting | Humans | Leukemia, Myeloid, Acute - genetics | Leukemia | Analysis | Index Medicus
Journal Article
Journal Article
Journal Article
Nature medicine, ISSN 1078-8956, 10/2017, Volume 23, Issue 10, pp. 1234 - 1240
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second/third generation c-Abl specific tyrosine kinase inhibitors (TKIs) has... 
Journal Article
Journal Article
Nature, ISSN 0028-0836, 06/2016, Volume 534, Issue 7607, pp. 341 - 346
Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR-ABL. Direct inhibition of... 
SURVIVAL | CD34(+) CELLS | INHIBITION | CHRONIC-PHASE | TYROSINE KINASE |